IMARC Group has recently released a new research study titled “United States Precision Medicine Market Size, Share, Trends and Forecast by Product, Technology, Application, End User, and Region, 2025-2033”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.

Market Overview

The United States precision medicine market size reached USD 38.4 Billion in 2024 and is expected to reach USD 43.2 Billion by 2033, growing at a CAGR of 11.7% during the forecast period of 2025-2033. This growth is driven by advancements in genomics, increased healthcare data, AI and machine learning adoption, government support, and the rising prevalence of chronic diseases.

Study Assumption Years

●     Base Year: 2024

●     Historical Year/Period: 2019-2024

●     Forecast Year/Period: 2025-2033

United States Precision Medicine Market Key Takeaways

●     Current Market Size: USD 38.4 Billion (2024)

●     CAGR: 11.7% (2025-2033)

●     Forecast Period: 2025-2033

●     The market is primarily driven by the widespread prevalence of chronic diseases such as cancer and cardiovascular conditions.

●     Government programs and investments encourage innovative healthcare solutions and funding for precision medicine.

●     Increasing integration of AI and big data analytics in healthcare enables more accurate patient profiling and personalized treatment.

●     Direct-to-consumer genetic testing services are improving patient awareness and engagement, fostering market growth.

●     Strategic partnerships between research centers and healthcare providers speed translation of research into clinical practice.

●     Rising interest in minimizing adverse drug reactions and improving treatment effectiveness stimulates demand for precision medicine.

Sample Request Link: https://www.imarcgroup.com/united-states-precision-medicine-market/requestsample

Market Growth Factors

The United States precision medicine market demand is rising steadily due to the increasing prevalence of chronic diseases, growing adoption of personalized therapies, and advancements in genomics and data-driven healthcare solutions. The U.S. Food & Drug Administration reports seven of the ten leading causes of death are common chronic conditions such as cardiovascular disease, diabetes, obesity, and cancer. Additionally, lifestyle factors like smoking which affects 28 million Americans increase the need for personalized therapies. These factors fuel demand for innovative therapeutic interventions tailored to individual patient profiles.

Technological advancements play a pivotal role in market growth. Ongoing improvements in genomics and bioinformatics enable better targeted therapies by analyzing genetic and molecular data. Accelerated investments by pharmaceutical companies in precision medicine research further advance drug development and personalized treatment options.

Government initiatives also support market expansion. Funding and programs encouraging innovation improve access to precision medicine solutions across healthcare systems. The integration of AI and big data analytics in healthcare enables more accurate patient profiling, enhancing treatment efficacy. The availability of direct-to-consumer genetic testing services increases patient awareness and engagement, driving demand further. Collaborative efforts between research centers and healthcare providers speed clinical adoption of precision medicine.

To get more information on this market Request Sample

Market Segmentation

Analysis by Product:

●     Consumables: Essential for diagnostic testing, sample collection, and processing, including reagents and test kits that ensure accurate diagnostic functioning.

●     Instruments: Include next-generation sequencing (NGS) platforms, PCR machines, and mass spectrometers, crucial for analyzing genetic information and biomarkers.

●     Services: Comprise genetic counseling, bioinformatics, data analysis, and laboratory testing that facilitate individualized treatment plan development.

Analysis by Technology:

●     Big Data Analytics: Processes large health datasets encompassing genetics and clinical observations to reveal individualized risk and therapy response patterns.

●     Bioinformatics: Interprets complex biological data like genetic sequences, helping predict disease risks and optimize personalized treatments.

●     Gene Sequencing: Identifies genetic mutations impacting disease susceptibility and drug response, supporting targeted therapy development.

●     Drug Discovery

●     Companion Diagnostics

●     Others

Analysis by Application:

●     Oncology: Focuses on personalizing cancer treatments based on individual genetic profiles to improve treatment efficacy and minimize side effects.

●     Central Nervous System (CNS): Targets neurological disorders like Alzheimer’s, Parkinson’s, and multiple sclerosis with personalized therapeutic strategies.

●     Immunology: Develops personalized immunotherapies for autoimmune diseases and cancer by modulating immune responses.

●     Respiratory Medicine

●     Infections

●     Others

Analysis by End User:

●     Hospitals and Clinics: Direct care providers where personalized therapies are administered for improved patient outcomes.

●     Diagnostic Centers: Offer genetic screening and diagnostic testing using technologies like NGS and liquid biopsy for treatment decisions.

●     Pharma and Biotech Companies: Lead drug development efforts, focusing on targeted therapies tailored to genetic profiles.

●     Healthcare IT Firms

●     Others

Regional Insights

The Northeast region stands out as a dominant contributor in the United States precision medicine market. It benefits from well-established healthcare infrastructures, top academic institutions, and advanced research facilities, especially in Massachusetts, New York, and Pennsylvania. This region hosts numerous biotechnology companies and medical research centers that drive clinical trials and pioneering personalized treatment innovations. Its robust ecosystem accelerates market growth and adoption of precision medicine solutions.

Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=20040&flag=C

Recent Developments & News

In 2024, several key developments advanced the U.S. precision medicine market: On October 31, Ataraxis AI launched Ataraxis Breast, an AI-native prognostic and predictive test for breast cancer, with a 30% accuracy improvement and USD 4 Million in seed funding. On October 23, four cancer research organizations started patient enrollment for myeloMATCH, a precision medicine clinical trial targeting AML and MDS. On April 3, Denovo Biopharma announced positive Phase 2b clinical trial results for DB104 in treatment-resistant depression, seeking global partners for further development. On February 19, NIH identified 275 million new genetic variants through the All of Us Research Program, enhancing data diversity.

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302